Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zytiga Cleared Fast In Refractory CRPC, Can It Also Move To Earlier Use?

Executive Summary

FDA’s speedy approval of Johnson & Johnson’s Zytiga (abiraterone) on April 28 – two months before the PDUFA date – paves the way for a third new advanced prostate cancer drug to get to market in a year and heralds the coming of even more competition in the valuable space.

Related Content

Data At ASCO From J&J Zytiga Trial’s Early End = Intel For Medivation’s MDV3100 Program
Eyeing Both A Partnership And An IPO, Aragon Takes $42M Series C
Tokai Raises $23 Million In Series D Financing
Positive Opinions in Europe For J&J's Zytiga And Telaprevir, Pfizer's Tafamidis And Orion's Dexmedetomidine
J&J Outlines Novel Cancer Strategy During Business Update
Dendreon Defends Provenge’s Stake Against Arrival Of Abiraterone
The Lesson Of Jevtana: With A Survival Advantage, All Things Are Possible
Prostate Cancer Market Snapshot: More Than Provenge
A Chock-Full Pipeline For Prostate Cancer Drugs
With Jevtana Approved For Advanced Prostate Cancer, Sanofi Could See Expansion To First-Line Use





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts